litlas
Log inCreate account

Donald Goff

Active 1988–2025

129
Papers
21,959
Citations
92
h-index
127
i10-index

Citations

Citations per year for Donald Goff1940: 1 citations1977: 1 citations1988: 1 citations1989: 1 citations1993: 4 citations1994: 4 citations1995: 5 citations1996: 18 citations1997: 14 citations1998: 14 citations1999: 49 citations2000: 47 citations2001: 65 citations2002: 73 citations2003: 166 citations2004: 198 citations2005: 228 citations2006: 276 citations2007: 284 citations2008: 288 citations2009: 322 citations2010: 291 citations2011: 297 citations2012: 257 citations2013: 275 citations2014: 228 citations2015: 208 citations2016: 166 citations2017: 165 citations2018: 136 citations2019: 487 citations2020: 397 citations2021: 424 citations2022: 305 citations2023: 165 citations2024: 287 citations2025: 117 citations2026: 3 citations1941–1976: no citations, so these years are not shown1978–1987: no citations, so these years are not shown1990–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,528 citing papers, 34.3% of this breakdownUnited Kingdom: 703 citing papers, 9.5% of this breakdownGermany: 462 citing papers, 6.3% of this breakdownCanada: 416 citing papers, 5.7% of this breakdownChina: 307 citing papers, 4.2% of this breakdownAustralia: 276 citing papers, 3.7% of this breakdownItaly: 226 citing papers, 3.1% of this breakdownNetherlands: 198 citing papers, 2.7% of this breakdownSpain: 184 citing papers, 2.5% of this breakdownSwitzerland: 161 citing papers, 2.2% of this breakdownFrance: 148 citing papers, 2% of this breakdownJapan: 143 citing papers, 1.9% of this breakdown
0%34.3%Other 21.9%

Institutions

Fields

  • Medicine46.9%
  • Neuroscience34.5%
  • Biochemistry, Genetics and Molecular Biology8.9%
  • Psychology5.8%
  • Health Professions0.7%
  • Computer Science0.6%
  • Other2.6%

Topics

  • Schizophrenia research and treatment13.2%
  • Functional Brain Connectivity Studies5.9%
  • Tryptophan and brain disorders4.7%
  • Neuroscience and Neuropharmacology Research4.4%
  • Advanced Neuroimaging Techniques and Applications2.5%
  • Bipolar Disorder and Treatment2.4%
  • Other66.9%

Coauthors

All papers

Open in search
  1. Reduced Sleep Spindles and Spindle Coherence in Schizophrenia: Mechanisms of Impaired Memory Consolidation?

    Authors: Erin J. Wamsley, Matthew A. Tucker, Ann K. Shinn, Kim E Ono, Sophia K. McKinley, Alice V. Ely, Donald Goff, Robert Stickgold, Dara S. Manoach - Biological Psychiatry 2011 cited by 504

  2. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice

    Authors: Georgios Schoretsanitis, John M. Kane, Christoph U. Correll, Stephen R. Marder, Leslie Citrome, John W. Newcomer, Delbert G. Robinson, Donald Goff, Deanna L. Kelly, Oliver Freudenreich, Daria Piacentino, Michael Paulzen, Andreas Conca, Gerald Zernig, Ekkehard Haen, Pierre Baumann, Christoph Hiemke, Gerhard Gründer - The Journal of Clinical Psychiatry 2020 cited by 141

  3. Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group

    Authors: Elias Wagner, Dan Siskind, Peter Falkai, Oliver Howes, Christoph U. Correll, Jimmy Lee, William G. Honer, John M. Kane, Emilio Fernández-Egea, Thomas R. E. Barnes, Alkomiet Hasan, TRRIP Working Group, Ofer Agid, Celso Arango, Lone Baandrup, Thomas R. E. Barnes, Andrea de Bartolomeis, Nico J.M. van Beveren, Michael L. Birnbaum, István Bitter, Alain Breier, Robert W. Buchanan, William T. Carpenter, David Castle, Eric Chen, Leslie Citrome, David Cotter, Christoph U. Correll, Benedicto Crespo‐Facorro, Michael Davidson, Richard Drake, Sonia Dollfus, Serdar Dursun, Bjørn H. Ebdrup, Robin Emsley, Emilio Fernández-Egea, Hélio Elkis, Peter Falkai, Wolfgang Fleischhacker, Oliver Freudenreich, Ary Gadelha, Wolfgang Gäebel, Birte Glenthøj, Donald Goff, Ariel Graff‐Guerrero, Jorge Hallak, Alkomiet Hasan, William G. Honer, Philip Homan, Oliver Howes, René S. Kahn, Stefan Kaiser, John M. Kane, James L. Kennedy, Bruce J. Kinon, Euitae Kim, Stephen M. Lawrie, Jimmy Lee, Stefan Leucht, F. Markus Leweke, Jan Libiger, Antony Loebel, James H. MacCabe, Stephen R. Marder, Robert A. McCutcheon, Ingrid Melle, Herbert Y. Meltzer, Armida Mucci, Dieter Naber, Shinchiro Nakajima, Jimmi Nielsen, Oisín O’Brien, Akin Ojagbemi, Christos Pantelis, Joseph Peuskens, Steven G. Potkin, Tiago Reis Marques, Thomas J. Raedler, Gary Remington, Susan L. Rossell, Jose Rubio-Lorente, Gabriele Sachs, Dan Siskind, Cynthia Siu, Iris E. Sommer, Jun Soo Kwon, Takefumi Suzuki, Jaana Suvisaari, Hiroyoshi Takeuchi, Rajiv Tandon, David Taylor, Neil Thomas, Jari Tiihonen, Hiroyuki Uchida, Alp Üçok, Daniel Umbricht, Ganesan Venkatasubramanian, Elias Wagner, James Walters, Chuanyue Wang and 2 more - Schizophrenia Bulletin 2023 cited by 38

  4. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial

    Authors: Jeffrey A. Lieberman, Robert E. Davis, Christoph U. Correll, Donald Goff, John M. Kane, Carol A. Tamminga, Sharon Mates, Kimberly E. Vanover - Biological Psychiatry 2015 cited by 258

  5. The Effects of Eszopiclone on Sleep Spindles and Memory Consolidation in Schizophrenia: A Randomized Placebo-Controlled Trial

    Authors: Erin J. Wamsley, Ann K. Shinn, Matthew A. Tucker, Kim E Ono, Sophia K. McKinley, Alice V. Ely, Donald Goff, Robert Stickgold, Dara S. Manoach - SLEEP 2013 cited by 126

  6. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

    Authors: Joseph P. McEvoy, Jonathan M. Meyer, Donald Goff, Henry A. Nasrallah, Sonia M. Davis, Lisa Sullivan, Herbert Y. Meltzer, John Hsiao, T. Scott Stroup, Jeffrey A. Lieberman - Schizophrenia Research 2005 cited by 1,139

  7. Aberrant resting-state functional connectivity of salience network in first-episode schizophrenia

    Authors: Huan Huang, Botao Zeng, Yuchao Jiang, Yingying Tang, Tianhong Zhang, XiaoChen Tang, Lihua Xu, Jijun Wang, Jin Li, Zhenying Qian, Xu Liu, Huiling Wang, Cheng Luo, Chunbo Li, Jian Xu, Donald Goff, Jijun Wang - Brain Imaging and Behavior 2019 cited by 54

  8. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia

    Authors: Stephan Heckers, Scott L. Rauch, Donald Goff, Cary R. Savage, Daniel L. Schacter, Alan J. Fischman, Nathaniel M. Alpert - Nature Neuroscience 1998 cited by 548

  9. Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

    Authors: Joseph T. Coyle, Guochuan Tsai, Donald Goff - Annals of the New York Academy of Sciences 2003 cited by 441

  10. The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia

    Authors: Donald Goff, Peter Falkai, W. Wolfgang Fleischhacker, Ragy R. Girgis, Rene Kahn, Hiroyuki Uchida, Jingping Zhao, Jeffrey A. Lieberman - American Journal of Psychiatry 2017 cited by 198

  11. A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia

    Authors: Donald Goff, J. Steven Lamberti, Andrew C. Leon, Michael F. Green, Alexander L. Miller, Jayendra K. Patel, Theo C. Manschreck, Oliver Freudenreich, Steve A. Johnson - Neuropsychopharmacology 2007 cited by 181

  12. Randomized Multicenter Investigation of Folate Plus Vitamin B 12 Supplementation in Schizophrenia

    Authors: Joshua L. Roffman, J. Steven Lamberti, Eric D. Achtyes, Eric A. Macklin, Gail C. Galendez, Lisa H. Raeke, Noah J. Silverstein, Jordan W. Smoller, Michele Hill, Donald Goff - JAMA Psychiatry 2013 cited by 150

  13. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

    Authors: Donald Goff, Lisa Sullivan, Joseph P. McEvoy, Jonathan M. Meyer, Henry A. Nasrallah, Gail L. Daumit, Steven Lamberti, Ralph B. D’Agostino, Thomas S. Stroup, Sonia M. Davis, Jeffrey A. Lieberman - Schizophrenia Research 2005 cited by 531

  14. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19

    Authors: Katlyn Nemani, Chenxiang Li, Mark Olfson, Esther Blessing, Narges Razavian, Ji Chen, Eva Petkova, Donald Goff - JAMA Psychiatry 2021 cited by 381

  15. Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages

    Authors: Dara S. Manoach, Katharine N. Thakkar, Eva Stroynowski, Alice V. Ely, Sophia K. McKinley, Erin J. Wamsley, Ina Djonlagic, Márk Vangel, Donald Goff, Robert Stickgold - Journal of Psychiatric Research 2009 cited by 159

  16. Failure of Neural Responses to Safety Cues in Schizophrenia

    Authors: Daphne J. Holt, Garth Coombs, Mohamed A. Zeidan, Donald Goff, Mohammed R. Milad - Archives of General Psychiatry 2012 cited by 124

  17. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers

    Authors: Joshua T. Kantrowitz, Jack Grinband, Donald Goff, Adrienne C. Lahti, Stephen R. Marder, Lawrence S. Kegeles, Ragy R. Girgis, Tarek Sobeih, Melanie M. Wall, Tse‐Hwei Choo, Michael F. Green, Yvonne S. Yang, Junghee Lee, Guillermo Horga, John H. Krystal, William Z. Potter, Daniel C. Javitt, Jeffrey A. Lieberman - Neuropsychopharmacology 2020 cited by 52

  18. Decreased basal ganglia and thalamic iron in early psychotic spectrum disorders are associated with increased psychotic and schizotypal symptoms

    Authors: Yu Veronica Sui, Faye McKenna, Hilary Bertisch, Pippa Storey, Rebecca Anthopolos, Donald Goff, Alexey Samsonov, Mariana Lazar - Molecular Psychiatry 2022 cited by 19

  19. A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia

    Authors: Donald Goff, Guochuan Tsai, James J. Levitt, Edward Amico, Dara S. Manoach, David Schoenfeld, Doug Hayden, Robert W. McCarley, Joseph T. Coyle - Archives of General Psychiatry 1999 cited by 434

  20. Racial/Ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA)

    Authors: Holly Kramer, Chien-Min Han, Wendy S. Post, Donald Goff, A DIEZROUX, R COOPER, Sujata Jinagouda, S SHEA - American Journal of Hypertension 2004 cited by 343

  21. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia

    Authors: Samuel M. Cohen, Richard W. Tsien, Donald Goff, Michael M. Halassa - Schizophrenia Research 2015 cited by 240

  22. Adverse Cardiac Effects Associated With Clozapine

    Authors: David B. Merrill, G. William Dec, Donald Goff - Journal of Clinical Psychopharmacology 2005 cited by 200

  23. The treatment of cognitive impairment in schizophrenia

    Authors: Donald Goff, Michele Hill, Deanna M. Barch - Pharmacology Biochemistry and Behavior 2010 cited by 195

  24. Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia

    Authors: A. Eden Evins, Sharyn M. Fitzgerald, Lara Wine, Roseanne Rosselli, Donald Goff - American Journal of Psychiatry 2000 cited by 174